Endocrine Abstracts

This study investigated risk of cardiovascular (CV) events over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1––84). The rhPTH(1–84)-treated patient cohort was derived from the NCT00732615 (REPLACE), NCT01...

Changes in estimated glomerular filtration rate (eGFR) over 5 years were evaluated in adult patients with chronic hypoparathyroidism. A cohort of patients treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), was derived from NCT01297309 (RACE) and NCT01199614 (HEXT) clinical trials. A historical control patient cohort with hypoparathyroidism who did not receive rhPTH(1–84) or rhPTH(1&#...

This study evaluated risk of chronic kidney disease (CKD) outcomes over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1–84). The cohort of patients with chronic hypoparathyroidism treated with rhPTH(1–84) was de...

Background: Little is known about the risk of developing nephrolithiasis and nephrocalcinosis in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). This study evaluated whether HypoPT is associated with increased risk of these conditions.Methods: This retrospective cohort study, based on a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of nephrolithiasis a...

Background: Previous studies of smaller size signaled heightened risk of CKD in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). However, little is known about CKD progression, including progression to end-stage kidney disease (ESKD), in HypoPT patients.Methods: A retrospective cohort study, using a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of CKD b...

Background: Prior small studies have suggested increased risk of cardiovascular (CV) conditions in patients with hypoparathyroidism (HypoPT). We evaluated whether chronic HypoPT is associated with increased risk of select CV hard endpoints (i.e., myocardial infarction (MI), stroke, and a composite CV endpoint) in a large contemporary cohort.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 - Q2 2017), was conducted ...

Standard therapy (ST) for chronic hypoparathyroidism (HPT) includes calcium and active vitamin D supplementation, which can be associated with an increased risk of renal complications. This study compared renal function change, assessed by estimated glomerular filtration rate (eGFR) over 5 years between HPT patients receiving rhPTH1-84 as an adjunct to ST and a historical control cohort without rhPTH1-84. rhPTH1-84-treated HPT patients were selected from two single-arm, long-t...